- Home
- MTEX vs CMMB Comparison
MTEX vs CMMB Comparison
Compare MTEX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- CMMB
- Stock Information
- Founded
- MTEX 1993
- CMMB 2004
- Country
- MTEX United States
- CMMB Israel
- Employees
- MTEX N/A
- CMMB 20
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- CMMB Health Care
- Exchange
- MTEX Nasdaq
- CMMB Nasdaq
- Market Cap
- MTEX 13.6M
- CMMB 20.9M
- IPO Year
- MTEX 1999
- CMMB N/A
- Fundamental
- Price
- MTEX $7.70
- CMMB $1.13
- Analyst Decision
- MTEX
- CMMB Strong Buy
- Analyst Count
- MTEX 0
- CMMB 3
- Target Price
- MTEX N/A
- CMMB $5.67
- AVG Volume (30 Days)
- MTEX 4.2K
- CMMB 148.4K
- Earning Date
- MTEX 11-05-2024
- CMMB 11-07-2024
- Dividend Yield
- MTEX N/A
- CMMB N/A
- EPS Growth
- MTEX N/A
- CMMB N/A
- EPS
- MTEX N/A
- CMMB N/A
- Revenue
- MTEX $122,380,000.00
- CMMB N/A
- Revenue This Year
- MTEX N/A
- CMMB N/A
- Revenue Next Year
- MTEX N/A
- CMMB N/A
- P/E Ratio
- MTEX N/A
- CMMB N/A
- Revenue Growth
- MTEX N/A
- CMMB N/A
- 52 Week Low
- MTEX $6.75
- CMMB $0.42
- 52 Week High
- MTEX $10.51
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- MTEX 56.09
- CMMB 28.21
- Support Level
- MTEX $7.30
- CMMB $1.29
- Resistance Level
- MTEX $7.96
- CMMB $1.59
- Average True Range (ATR)
- MTEX 0.20
- CMMB 0.17
- MACD
- MTEX -0.00
- CMMB -0.06
- Stochastic Oscillator
- MTEX 69.15
- CMMB 4.41
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.